Neogen, Henry Schein, Evolent Health Flagged as Cautious Healthcare Picks

Neogen (NEOG), Henry Schein (HSIC), and Evolent Health (EVH) face headwinds warranting investor caution, according to a StockStory report published on May 29, 2026. The three healthcare companies are highlighted as stocks to avoid amid a sector that has trailed the broader market. Neogen, with a market capitalization of $2.02 billion, trades at 36.3 times forward earnings. Henry Schein’s $8.69 billion valuation reflects a 13.9x forward multiple, while Evolent Health, at $438.7 million, carries a 14.5x forward price-to-earnings ratio. The healthcare sector posted a 4.1% gain over the past six months, significantly underperforming the S&P 500’s 10.3% advance, as COVID inventory destocking and regulatory uncertainties weigh on earnings potential.